UNSPSC 51283005: Clindamycin palmitate hydrochloride

This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VN9A8JM7M7, chemically known as methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside 2-palmitate monohydrochloride but more generally known as clindamycin palmitate hydrochloride, which bears US NIH Compound Identifier 33030.

UNSPSC 51283005 Clindamycin palmitate hydrochloride is a Commodity code for a specific antibiotic pharmaceutical product, but recent state and local procurement activity tagged to this code does not reflect purchases of clindamycin palmitate hydrochloride itself. Instead, the tagged opportunities show state and local health agencies procuring other pharmaceutical products — notably naloxone (opioid reversal) and safe drug deactivation systems through Seminole County, Florida, and a prior award to Chartwell Rx LLC by the Illinois Department of Public Health for doxycycline hyclate and ciprofloxacin hydrochloride under a cooperative purchasing vehicle (MMCAP Infuse). The mismatch between the code's nominal scope and the actual recent procurement activity signals that either these opportunities were miscoded or the code sees minimal current demand for clindamycin palmitate hydrochloride specifically. Issuing bodies using this code include state health departments and county health authorities, with recent activity originating from Florida and Illinois. No standing set-aside or preference programs are documented in the recent records.

The geographic spread is limited to two states with available records — Florida and Illinois — based on the two most recent opportunities. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023, though the due date appears to be a data anomaly) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, submitted electronically through the county e-Procurement Portal and potentially funded through FEMA. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical contract (solicitation 26482DPHPREPDB53392, closed August 28, 2026) through MMCAP Infuse to Chartwell Rx LLC totaling $2,999,999.11 over three years for doxycycline and ciprofloxacin products, not clindamycin. The code shows sparse recent activity directly aligned with its stated commodity definition, warranting verification of coding accuracy before pursuing opportunities.